Dr. Ahmed Alwabari
panellist
Consultant oncology KFSHD
09:45 –10:30
Friday 3-5-2024 Day 1
Role of anthracyclines in early breast cancer
- When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer
When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer
Moderator:
Dr. Meteeb Alfohaidi
Panel:
15:00-15:45
Friday 3-5-2024 Day 1
Genomic tools in breast cancer
- chemotherapy in high risk lobular/mucinous BC?
- Neoadjuvant therapy in premenopausal patients with lobular BC?
Adjuvant therapy with node negative and node positive lobular BC?
Adjuvant therapy in luminal BC with RS 16-25?
Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours?? - Oncotype DX and selection of neoadjuvant hormonal vs chemotherapy therapy
- Role of interval Ki67 assessment with neoadjuvant hormonal therapy
Moderator: 
Ahmed Alshehri
Panel:
